Monoclonal antibodies are becoming therapeutic agents of choice to treat many inherited and acquired diseases. Different strategies can be used to generate new antibodies but generic immunization is currently the only method capable of overcoming the difficulties of in vitro antigen production.
Existing genetic immunization technologies, including naked DNA and electrotransfer, are not, however, able to efficiently produce all required antibodies. By contrast, ICANtibodies is a potent, "one-way" process based on a revolutionary nanotaxi for the development of virtually any desired antibodies starting simply from an available in silico DNA antigenic sequence.
Some features of ICANtibodies:
Some benefits of ICANtibodies:
Let MédiMabs assist you in tailoring this innovative technology to your needs. Please contact us to obtain more information.